Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597390 | 0.86 | CYP4F2 (0.30) | CYP4F2CYP4A11 | |
| SCHEMBL47526 | 0.80 | CYP4F2 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL16675249 | 0.78 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL18730811 | 0.77 | GRIN2D (0.45) | — | |
| SCHEMBL2597342 | 0.77 | CYP2C9 (0.37) | — | |
| SCHEMBL12345780 | 0.77 | DGAT1 (0.31) | — | |
| SCHEMBL807413 | 0.77 | PRKCA (0.42) | CYP4F2CYP4A11 | |
| SCHEMBL11987677 | 0.73 | — | — | |
| SCHEMBL10089283 | 0.72 | ALDH1A1 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL2282104 | 0.71 | CYP4F2 (0.50) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2571862-A1 | PRODRUG OF TRIAZOLONE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2011145747-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011145747-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | F7, TFPI, TFPI2 | CYP4F2 60/4885CYP4A11 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.